Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17828
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Chicago, Illinois. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 313–324 of 17,828 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 3 Interventional

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Durvalumab, Placebo, (Osimertinib cohort, single-arm, open-label separate cohort)
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
80
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

NCT04150497
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
UCART22, CLLS52
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
12 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Phase 2 Interventional

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

NCT06649812
View directory record Official record
Conditions
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography, Prednisone, Venetoclax
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
115
States / cities
Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 94 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Completed Phase 2 Interventional Results available

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

NCT05936151
View directory record Official record
Conditions
Overweight or Obesity, CKD, Type 2 Diabetes
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Not applicable Interventional

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

NCT05866419
View directory record Official record
Conditions
Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Interventions
ThecaFlex DRx System
Device
Lead sponsor
Alcyone Therapeutics, Inc
Industry
Eligibility
3 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
17
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Not applicable Interventional

The REACH-OUT Trial

NCT07540143
View directory record Official record
Conditions
Hypertension, Reproductive Behavior, Primary Health Care, Electronic Health Record
Interventions
Health literacy-informed patient education materials, BP monitor, brief orientation, and portal tools, The MeDS assessment, Patient navigator support
Other · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Phase 2 Interventional

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

NCT06865105
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Lutikizumab, Risankizumab, ABBV-701, ABBV-547
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
19
States / cities
Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

NCT04640142
View directory record Official record
Conditions
Primary Immune Deficiency
Interventions
Newnorm
Biological
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

NCT07808697
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1283, mRNA-1273
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
6 Months to 11 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
13
States / cities
Ontario, California • Miami, Florida • Miami Lakes, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST
Enrolling by invitation Phase 2Phase 3 Interventional

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2026 · Synced Nov 13, 2026, 1:13 AM EST